Does Pretransplant Soluble CD30 Serum Concentration Affect Deceased-Donor Kidney Graft Function 3 Years After Transplantation?

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1357-1361

  Kovac, J ^a   Arnol, M ^a   Vidan Jeras, B ^a   Bren, A F ^a   Kandus, A ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD30 ANTIGEN; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; SOLUBLE CD30 ANTIGEN;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; BLOOD LEVEL; BODY MASS; CADAVER DONOR; CALCULATION; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MODIFICATION OF DIET IN RENAL DISEASE STUDY EQUATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SERUM;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, CD30; CADAVER; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REOPERATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; TISSUE DONORS;

EID: 45449103078     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.092     Document Type: Article

References (26)

1. Josimovic-Alasevic O., Durkop H., Schwarting R., et al. Ki-1 (CD30) antigen is released by Ki-1 positive tumor-cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzymw-linked immunosorbent assay. Eur J Immunol 19 (1989) 157
2. Del Prete G., De Carli M., D'Elios M.M., et al. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 182 (1995) 1655
3. + T cells producing Th2-type cytokines. FASEB J 9 (1995) 81
4. Romagnani S., Parronchi P., D'Elios M.M., et al. An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 113 (1997) 153
5. Pelzl S., Opelz G., Wieser M., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73 (2002) 3
6. Süsal C., Pelzl S., Dohler B., et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13 (2002) 1650
7. Süsal C., Pelzl S., and Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 76 (2003) 1231
8. Süsal C., Pelzl S., Simon T., et al. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 36 (2004) 29
9. Cinti P., Pretagostini R., Arpino A., et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 79 (2005) 599
10. Ravindra R., Naina J., Mira V., et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplantation 5 (2005) 1922
11. Kim M.S., Kim H.J., Kim S.I., et al. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation 82 (2006) 1602
12. Kandus A., Grego K., Arnol M., et al. Effective immunoprophylaxis with basiliximab plus triple therapy in renaltransplantation: five-year single-center experience. Transplant Proc 38 (2006) 2853
13. Kandus A., Grego K., and Bren A.F. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients. Ther Apher Dial 9 (2005) 262
14. Pöge U., Gerhardt T., Palmedo H., et al. MDRD equations for estimation of GFR in renal transplant patients. Am J Transplantation 5 (2005) 1306
15. Poggio E.D., Wang X., Weinstein D.M., et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplantation 6 (2006) 100
16. Terasaki P.I., and McCleland J. Microdroplet assay of human serum cytotoxins. Nature 204 (1964) 998
17. Kasiske B.L., Vazquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11 suppl 15 (2000) S1
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kindey Dis 39 2 suppl 1 (2002) S1
19. Heinemann F.M., Rebmann V., Witzke O., et al. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 83 (2007) 706
20. Fattovich G., Vinante F., Giustina G., et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 103 (1996) 105
21. Terasaki P.I., Gjertson D.W., Cecka J.M., et al. Significance of the donor age effect on kidney transplants. Clin Transplant 11 (1997) 366
22. Meier-Kriesche H.U., Arndorfer J.A., and Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 73 (2002) 70
23. Womer K.L., Vella J.P., and Sayegh M.H. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 20 (2000) 126
24. Ojo A.O., Wolfe R.A., Held P.J., et al. Delayed graft function:risk factors and implications for renal allograft survival. Transplantation 63 (1997) 968
25. Magee J.C., Barr M.L., Basadonna G.P., et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant 7 (2007) 1424
26. Langan L.L., Park L.P., Hughes T.L., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplantation 7 (2007) 847